论文部分内容阅读
心力衰竭(HF)是指由心脏结构或功能异常导致心室收缩或舒张能力受损进而引起一系列病理生理变化的临床综合征。HF是大多数心血管疾病的最终归宿,其患病人口、死亡率及医疗支出在世界范围内均占据重要比重。为了更有效地治疗HF、提高患者的生存率,新型HF治疗药物的研究不断深入。新型HF治疗药物包括双效神经激素调节剂、强心剂、血管活性多肽与心肌保护剂。本文简要综述近年治疗HF新型药物的研究进展。
Heart failure (HF) is a clinical syndrome characterized by a series of pathophysiological changes resulting from impaired ventricular systole or diastole caused by structural or functional abnormalities in the heart. HF is the ultimate fate of most cardiovascular diseases and its prevalence, mortality and health care expenditures account for a significant share of the world population. In order to treat HF more effectively and improve the survival rate of patients, the research of new HF therapeutic drugs continues to deepen. New HF therapies include dual-acting neurohormonal regulators, cardiotonics, vasoactive peptides and cardioprotective agents. This article briefly reviews recent research progress in the treatment of HF new drugs.